Vanderstichele, Hugo

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 2,065

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,818

Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 724

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 660

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 573

CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease

Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 456

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 450

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 439

Tau and Aβ42 in Cerebrospinal Fluid from Healthy Adults 21–93 Years of Age: Establishment of Reference Values

Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 436

Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease: A Comparative Cerebrospinal Fluid Study

Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 434

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 358

Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma

Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 301

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 258

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry

Prion Diseases and Protein MisfoldingAlzheimer's disease research and treatments

Cited by 238

Machine learning for comprehensive forecasting of Alzheimer’s Disease progression

Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports

Dementia and Cognitive Impairment ResearchMachine Learning in Healthcare

Cited by 223

Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 194

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 136

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 136

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 133

Neurofilament ELISA validation

Petzold, A., Altintas, A., Andreoni, L., Bartos, A., Berthele, A., Blankenstein, M. A., Buee, L., Castellazzi, M., Cepok, S., Comabella, M., et al. (2010) · Journal of Immunological Methods

Clinical Laboratory Practices and Quality ControlReliability and Agreement in Measurement

Cited by 105

Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition

Schelle, J., Häsler, L. M., Göpfert, J. C., Joos, T. O., Vanderstichele, H., Stoops, E., Mandelkow, E., Neumann, U., Shimshek, D. R., Staufenbiel, M., et al. (2017) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 40

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia

Illán‐Gala, I., Pegueroles, J., Montal, V., Alcolea, D., Vilaplana, E., Bejanin, A., Borrego‐Écija, S., Sampedro, F., Subirana, A., Sánchez‐Saudinós, M., et al. (2019) · Annals of Clinical and Translational Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 20